COVID-19 and Liver injury: hepatology perspectives
Received Date: May 19, 2020 / Accepted Date: Jul 21, 2020 / Published Date: Jul 27, 2020
Abstract
SARS-CoV-2, a severe acute respiratory syndrome caused by Coronavirus 2, discovered in 2019 in China, is responsible for the current pandemic declared by the WHO since March 2020. The clinical syndrome caused by Covid-19 has a broad spectrum of severity. The most common clinical manifestations are fever, dry cough, dyspnea, fatigue, and anosmia. The virus binds to receptors for angiotensin-converting enzyme 2 (ECA2) and serine protease TMPRSS2 for protein S initiation, which are expressed not only in the lungs but also in the liver, colonic, esophageal and biliary epithelial cells. In this context, the liver is a potential target for COVID-19 infection. Liver damage occurs during the course and treatment of viral infection in patients with or without previous liver disease. Therefore, the characteristics of liver injury associated with COVID-19 were reviewed based on research related, in the context of the pandemic.
Keywords: COVID-19 virus infection; SARS-CoV-2 infection; Coronavirus Infections; Liver; Liver Diseases; Liver Dysfunctions.
Citation: Bocchese NV, Dávila NG, Rodrigues MBM, Araújo-Neto I, Costa MO, et al. (2020) COVID-19 and Liver Injury: Hepatology Perspectives. J Gastrointest Dig Syst 10: 621. Doi: 10.4172/2161-069X.1000621
Copyright: © 2020 Bocchese NV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 1740
- [From(publication date): 0-2020 - Dec 22, 2024]
- Breakdown by view type
- HTML page views: 1155
- PDF downloads: 585